News for Humacyte, Inc. (HUMA)

The biotechnology sector is witnessing a notable increase in search activity for several companies, among which Rhythm Pharmaceuticals (RYTM) stands out with a

Humacyte, Inc. (HUMA) closed at $1.45 in the latest trading session, marking a -0.68% move from the prior day.

BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for the target cut. The analyst views Humacyte’s early commercial traction as evidence of the “game-changing nature” of its Acellular Tissue Engineered Vessel. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >>

Humacyte (HUMA) shares plunged to a historic low of $1.76, a drop of approximately 7%, after releasing Q4 2024 earnings that exceeded predictions with a GAAP EP

Humacyte faces challenges as shares hit record lows, despite beating Q4 2024 EPS estimates. Read more here.

Humacyte, Inc. (NASDAQ:HUMA) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ETCompany ParticipantsThomas Johnson - Director, Corporate...

Humacyte (HUMA) disclosed a fourth-quarter GAAP loss per share of $0.16, while maintaining a solid cash position. The company reported cash, cash equivalents, a

- Received U.S. Food and Drug Administration (FDA) approval of Symvessâ„¢ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trau

Humacyte (HUMA) is set to release its fourth-quarter earnings before the market opens on March 28th. Analysts project an EPS of -$0.26 with no expected revenue.

Humacyte, Inc.'s stock fell 25% amid $50M fundraising and safety concerns on FDA-approved Symvess. Click for this updated look at HUMA stock prospects.

The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Switzerland-based OSR Holdings, Inc. (OSRH) is up over 173 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday. Shares of Chewy, Inc. CHWY fell sharply in pre-market t...

U.S. stock futures were trading lower on Wednesday, after advancing for three consecutive sessions. Futures of major benchmark indices were lower in premarket trading.

Shares of GameStop Corp. GME rose sharply in today's pre-market trading after reporting better-than-expected fourth-quarter earnings. GameStop reported fourth-...

Humacyte, Inc. (HUMA) closed the most recent trading day at $3.96, moving -1.25% from the previous trading session.

Humacyte, Inc. (HUMA) concluded the recent trading session at $4.30, signifying a -1.6% move from its prior day's close.

Humacyte, Inc. (HUMA) concluded the recent trading session at $4.37, signifying a +1.63% move from its prior day's close.